['\xe2\x86\x91 INDICATES INCREASE. \xe2\x86\x93 INDICATES DECREASE. A THE DOSING RECOMMENDATION FOR COADMINISTRATION OF DIDANOSINE DELAYED-RELEASE CAPSULES AND TENOFOVIR DISOPROXIL FUMARATE WITH RESPECT TO MEAL CONSUMPTION DIFFERS FROM THAT OF DIDANOSINE. SEE THE COMPLETE PRESCRIBING INFORMATION FOR DIDANOSINE DELAYED-RELEASE CAPSULES.', 'CIPROFLOXACIN', '\xe2\x86\x93 CIPROFLOXACIN CONCENTRATION', 'ADMINISTER DIDANOSINE AT LEAST 2 HOURS AFTER OR 6 HOURS BEFORE CIPROFLOXACIN.', 'DELAVIRDINE', '\xe2\x86\x93 DELAVIRDINE CONCENTRATION', 'ADMINISTER DIDANOSINE 1 HOUR AFTER DELAVIRDINE.', 'GANCICLOVIR', '\xe2\x86\x93 DIDANOSINE CONCENTRATION', 'IF THERE IS NO SUITABLE ALTERNATIVE TO GANCICLOVIR, THEN USE IN COMBINATION WITH DIDANOSINE WITH CAUTION. MONITOR FOR DIDANOSINE-ASSOCIATED TOXICITY.', 'INDINAVIR', '\xe2\x86\x93 INDINAVIR CONCENTRATION', 'ADMINISTER DIDANOSINE 1 HOUR AFTER INDINAVIR.', 'METHADONE', '\xe2\x86\x93 DIDANOSINE CONCENTRATION', 'DO NOT COADMINISTER METHADONE WITH DIDANOSINE PEDIATRIC POWDER DUE TO SIGNIFICANT DECREASES IN DIDANOSINE CONCENTRATIONS. IF COADMINISTRATION OF METHADONE AND DIDANOSINE IS NECESSARY, THE RECOMMENDED FORMULATION OF DIDANOSINE IS DIDANOSINE DELAYED-RELEASE CAPSULES. PATIENTS SHOULD BE CLOSELY MONITORED FOR ADEQUATE CLINICAL RESPONSE WHEN DIDANOSINE DELAYED-RELEASE CAPSULES ARE COADMINISTERED WITH METHADONE, INCLUDING MONITORING FOR CHANGES IN HIV RNA VIRAL LOAD.', 'NELFINAVIR', '\xe2\x86\x93 NO INTERACION 1 HOUR AFTER DIDANOSINE', 'ADMINISTER NELFINAVIR 1 HOUR AFTER DIDANOSINE.', 'TENOFOVIR DISOPROXIL FUMARATE', '\xe2\x86\x93 DIDANOSINE CONCENTRATION', 'A DOSE REDUCTION OF DIDANOSINE TO THE FOLLOWING DOSAGE ONCE DAILY IS RECOMMENDED. A 250 MG (ADULTS WEIGHING AT LEAST 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN) 200 MG (ADULTS WEIGHING LESS THAN 60 KG WITH CREATININE CLEARANCE OF AT LEAST 60 ML/MIN) DIDANOSINE AND TENOFOVIR DISOPROXIL FUMARATE MAY BE TAKEN TOGETHER IN THE FASTED STATE. IF TENOFOVIR DISOPROXIL FUMARATE IS TAKEN WITH FOOD, DIDANOSINE SHOULD BE TAKEN ON AN EMPTY STOMACH (AT LEAST 30 MINUTES BEFORE FOOD OR 2 HOURS AFTER FOOD). PATIENTS SHOULD BE MONITORED FOR DIDANOSINE\xc2\xad-ASSOCIATED TOXICITIES AND CLINICAL RESPONSE.']